Metagenomi Therapeutics Inc. (MGX) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Metagenomi Therapeutics Inc. (NASDAQ: MGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $0.76 (-3.24% 1D, market cap $29.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MGX ranks #953 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MGX carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GNTA (Genenta Science S.p.A.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $29.8M) and ALGS (Aligos Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, MGX leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).
Per MGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785279), Metagenomi Therapeutics Inc. generated $25.2M in revenue (-51.8% YoY), -$87.9M in net income, and -$89.5M in free cash flow against $221.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.9 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While MGX currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.03) and Max Pain ($0.80) forces dealer call-delta covering toward $2.68.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Metagenomi Therapeutics Inc. (MGX) dropped -3.24% to $0.76, trading at 2% of its 52-week range ($0.75 – $2.55). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
BigGo Finance report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
BigGo Finance report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
BigGo Finance report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX) shares moved
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -51.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MGX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MGX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Metagenomi Therapeutics Inc. (MGX) ranks #953 by composite RQD confidence (23/100, grade E) and #801 by equity capitalization ($29.5M). Within this direct 5-issuer industry benchmark cohort, MGX leads on earnings valuation at N/A trailing P/E, while MGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GNTA currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with MGX at 23/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MGX
ACTIVE
Metagenomi Therapeutics Inc. | E | 23/100 | — | — | -35.0% | -3.24% | $29.5M | Benchmark Subject |
| GNTA Genenta Science S.p.A. | D | 50/100 | — | — | — | +32.07% | $29.8M | /gnta-vs-mgx → |
| ALGS Aligos Therapeutics Inc. | E | 20/100 | — | — | -35.0% | -4.17% | $30.0M | /algs-vs-mgx → |
| ESLA Estrella Immunopharma Inc. | D- | 38/100 | — | — | -35.0% | -33.32% | $27.8M | /esla-vs-mgx → |
| EVAX Evaxion A/S | D | 46/100 | — | — | — | -0.34% | $26.4M | /evax-vs-mgx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Metagenomi Therapeutics Inc. (MGX) reported GAAP revenue of $25.2M (-51.8% vs. FY2024 revenue of $52.3M , and -43.7% cumulative change since FY2023) , GAAP net income of -$87.9M, operating cash flow of -$88.9M, and free cash flow of -$89.5M (+20.3% YoY). On the balance sheet, MGX closed FY2025 with $221.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $25.2M | -$87.9M | -$88.9M | -$89.5M | $221.1M | — |
| FY2024 (FY) | 2024-12-31 | $52.3M | -$78.1M | -$109.1M | -$112.2M | $324.6M | — |
| FY2023 (FY) | 2023-12-31 | $44.8M | -$68.3M | -$91.4M | -$91.4M | — | — |
As of 2026-11-03, Metagenomi Therapeutics Inc. (NASDAQ: MGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $0.76 (-3.24% 1D, market cap $29.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MGX ranks #953 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MGX carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GNTA (Genenta Science S.p.A.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $29.8M) and ALGS (Aligos Therapeutics Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, MGX leads on earnings multiple (N/A) while MGX leads on capital efficiency (-35.0% ROIC).
Per MGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001785279), Metagenomi Therapeutics Inc. generated $25.2M in revenue (-51.8% YoY), -$87.9M in net income, and -$89.5M in free cash flow against $221.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MGX last traded at $0.76 (-3.24% on volume of 224,547 shares), positioning the stock -26.21% below its 50-day simple moving average ($1.03) and -40.63% below its 200-day simple moving average ($1.28). Across its 52-week range of $0.75 to $2.55, MGX sits at the 0.6% percentile with a 14-day RSI of 34.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.86).
The MGX scores 24 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
The RQD framework weighs these factors heavily toward caution.
Metagenomi Therapeutics Inc. (MGX) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances). The company reported revenue of $25.2M for FY 2025, indicating it generates some revenue alongside substantial operating losses. — describes its customers or specific products and revenue model.
Revenue declined from $52.3M in FY 2024 to $25.2M in FY 2025, while net losses widened from -$78.1M to -$87.9M. Per the market data, operating margin and net margin are both -60%, gross margin is 0%, and ROIC is -35%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 1/9, both consistent with significant financial distress. Debt/Equity is 0.5; the debt figures themselves are N/A in the SEC financials.
Supply_chain is NONE and there are no butterfly_links. Upstream and downstream dependencies are — Sector correlations beyond the stated sector (Health Care) and industry (Biotechnology: Biological Products) are — Investors should watch for 2nd-order bottlenecks in clinical, manufacturing, or partnership dependencies, none of which are identified in the source data.
Real-time company headlines, analyst actions, and sector developments for Metagenomi Therapeutics Inc. (MGX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
BigGo Finance report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
BigGo Finance report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
BigGo Finance report covering Metagenomi Therapeutics Inc. (MGX) market action, institutional positioning, and fundamental catalysts.
Revenue of $25.2M in FY 2025 and a 1.03% price gain on the day show the company still generates sales and has some trading momentum.. When you look under the hood at MGX, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $2.55. My 12M target is $0.94.
@CreditSpread_Watch Shorting a 3/20 institutional whale-flow stock at $0.78 is dangerous when funds are rotating into Health Care.
A -35% ROIC, 0% FCF yield, Altman Z-Score of 0.2, and Piotroski F-Score of 1/9 point to severe financial distress and forensic balance-sheet risk.. Look at the math on MGX: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $0.69 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).